Genentech’s ipatential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints

Genentech, a member of the roche group (six: ro, rog; otcqx: rhhby), today announced that the phase iii ipatential150 study met its co-primary endpoin

ADT Ratings Summary

ADT Quant Ranking